Feature | Atrial Fibrillation | January 30, 2019

New Atrial Fibrillation Guidelines Recommend NOACs Over Warfarin

Newer anticoagulants are now the preferred alternative over the old standard of care

Rivaroxaban is among four new oral anticoagulants (NOAC) now recommended by atrial fibrillation guidelines over the old standard of warfarin.

Rivaroxaban is among four new oral anticoagulants (NOAC) now recommended by atrial fibrillation guidelines over the old standard of warfarin.

 

January 30, 2019 — Updated atrial fibrillation (AFib) treatment guidelines released this week now recommend new oral anticoagulants (NOACs) as the preferred alternative to warfarin for reducing the risk of stroke. This change was made in a focused update this week to the 2014 American Heart Association (AHA), American College of Cardiology (ACC) and Heart Rhythm Society (HRS) Guideline for the Management of Patients With Atrial Fibrillation.[1] The focused update was published simultaneously in the AHA journal Circulation, Journal of the ACC and the HRS journal, HeartRhythm. 

Anticoagulants have long been recommended to reduce the risk of stroke in patients with AFib who have an increased risk of thromboembolism. Warfarin has been used as the standard of care in these patients for years, but the drug has a very narrow therapeutic window requiring regular blood tests to ensure the level of warfare in the blood remains therapeutic. The protective effects of the drug also is impacted by vitamin K, so foods rich in vitamin K like green leafy vegetables can decrease its effect. 

The newer class of non-vitamin K oral anticoagulants offers several advantages, such as eliminating the need for regular blood tests and not being impacted by vitamin K levels. NOACs are now the preferred recommended drug class over the traditional warfarin, unless patients have moderate to severe mitral stenosis or have an artificial heart valve. NOACs include dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis) and edoxaban (Savaysa).

“Patients with AFib are at increased risk of stroke, which can be devastating. A goal of treating AFib patients is to make blood less likely to form clots, which reduces the risk of stroke. New scientific studies show that NOACs may be safer for patients because there is less risk of bleeding, and they may also be more effective at preventing blood clots than warfarin,” said Craig T. January, M.D., Ph.D., co-chair of the focused update group. He is a professor of cardiovascular medicine at the University of Wisconsin in Madison.

The guidelines rank recommendations as strong, weak or harmful on the basis of the quality and quantity of the scientific research that supports each recommendation. Recommendations with the highest level of evidence have more than one randomized controlled trial reporting similar results, whereas the lowest-ranked recommendations are based on the clinical experience of experts. 

 

Weight Loss Added to Giuidelines

The new guidelines now include recommending weight loss for overweight or obese AFib patients. Studies find that losing weight can reduce the health risks associated with or even reverse AFib. It can also help lower blood pressure. High blood pressure is often associated with AF.

 

Reveral Agents Available for NOACs

The guidelines also point out that new drugs are now available to reverse the effect of NOACs. These reversal agents, while used infrequently, are helpful when there are signs of severe bleeding caused by a NOAC or when a patient on a NOAC needs an emergency surgical procedure

“AFib patients should talk to their healthcare provider about any concerns they have about their prescribed medications and whether or not losing weight would benefit their health,” said January.

The new guidelines also suggest that NOACs could even be used in people at lower risk of stroke than previously thought. Although the evidence for this recommendation is not yet definitive, emerging research is beginning to suggest that the benefit of NOACs for reducing stroke risk outweighs the risk of taking them, said January.

Co-authors of the guideline update include L. Samuel Wann, M.D. (co-chair); Hugh Calkins, M.D.; Lin Y. Chen, M.D.; M.S., Joaquin Cigarroa, M.D.; Joseph C. Cleveland, Jr., M.D.; Patrick T. Ellinor, M.D., Ph.D.; Michael Ezekowitz, MBChB, D.Phil.; Michael E. Field, M.D.; Karen Furie, M.D.; MPH, Paul Heidenreich, M.D.; Katherine T. Murray, M.D.; Julie B. Shea, M.S.; RNCS, Cynthia M. Tracy,  M.D. and Clyde W. Yancy, M.D. 

 

 

How AFib Causes a Stroke

AFib is a type of irregular heartbeat in the atria, or upper chambers of the heart. Because the heartbeat is irregular, blood can pool and then clot inside the atria, particularly in the left atrial appendage (LAA), a pouch that is part of the anatomy of the upper left chamber of the heart. If the clots formed within the left atrium migrate within the blood and reach the brain, a stroke caused by a blocked artery can occur even in people with no obvious symptoms of A-Fib.

Blood-thinning medications called anticoagulants have long been recommended to reduce the risk of stroke in patients with AF who have an increased risk of thromboembolism (a blockage of a blood vessel by a clot travelling in the bloodstream) and/or stroke caused by narrowed or blocked arteries. 

 

 

Related NOAC Content:

Advantages and Disadvantages of Novel Oral Anticoagulants

FDA Clears First Reversal Agent for Rivaroxaban, Apixaban Anticoagulants

First Head-to-Head Comparison of Novel Oral Anticoagulants in Matched Population for Costs, Resource Utilization

Most Atrial Fibrillation Patients Do Not Get Preventive Drug Before Stroke

Warfarin Use May Not Bring Long-Term Stability for Atrial Fibrillation

Newer Anticoagulant Reduces Major Bleeds in AF Ablation

 

 

Reference:

1. Craig T. January, L. Samuel Wann, Hugh Calkins, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. Originally published 28 Jan 2019. https://doi.org/10.1161/CIR.0000000000000665Circulation. 2019;0

 

 

 

Related Content

Fragmin (dalteparin sodium) injection was cleared by the FDA for use in pediatric patients. It was initially approved by the FDA in 1994 for adults and is a type of heparin.

Fragmin (dalteparin sodium) injection is now cleared by the FDA for use in pediatric patients. It was initially approved by the FDA in 1994 for adults and is a type of heparin.

Technology | Antiplatelet and Anticoagulation Therapies | May 17, 2019
May 17, 2019 — The U.S.
PhaseBio Receives FDA Breakthrough Therapy Designation for Ticagrelor Reversal Agent
Technology | Antiplatelet and Anticoagulation Therapies | April 30, 2019
PhaseBio Pharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy...
People With Heart Disease at Risk When Pharmacies Close
News | Antiplatelet and Anticoagulation Therapies | April 24, 2019
April 24, 2019 — New research from the University of Illinois at Chicago shows that when pharmacies close, people sto
Study Finds Only Six Percent of Patients Taking Statins as Directed
News | Antiplatelet and Anticoagulation Therapies | April 18, 2019
A recent study found patients with atherosclerotic cardiovascular disease cut their risk of a second major adverse...
HonorHealth Research Institute Launches SynIVUS-DAPT Study
News | Antiplatelet and Anticoagulation Therapies | April 16, 2019
HonorHealth Research Institute announced the first patients have been enrolled in the SynIVUS-DAPT Study. The clinical...
Lack of Physician Guidance, Fear of Side Effects Influence Statin Compliance
News | Antiplatelet and Anticoagulation Therapies | April 15, 2019
Despite national guidelines indicating statins can lower risk of heart attack and stroke, many patients who could...
Stopping DAPT After One Month Improved Outcomes in Stent Patients
News | Antiplatelet and Anticoagulation Therapies | March 25, 2019
Patients who stopped taking aspirin one month after receiving a stent in the heart’s arteries but continued taking the...
Apixaban Effective in Specific Cohort of Non-Valvular Atrial Fibrillation Patients
News | Antiplatelet and Anticoagulation Therapies | March 19, 2019
The Bristol-Myers Squibb-Pfizer Alliance announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis (apixaban...
Researchers Develop Reversible, Drug-Free Antiplatelet Therapy
News | Antiplatelet and Anticoagulation Therapies | February 19, 2019
A new reversible, drug-free antiplatelet therapy could reduce the risk of blood clots and potentially prevent cancer...
FDA Approves Portola Pharmaceuticals' Prior Approval Supplement for Andexxa Generation 2 Manufacturing Process
News | Antiplatelet and Anticoagulation Therapies | January 02, 2019
The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals’ Prior Approval Supplement (PAS) for...
Overlay Init